Gemtuzumab ozogamicin + Liposomal daunorubicin + Mitoxantrone + Fludarabine + Cytarabine + Busulfan + Cyclophosphamide
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukaemia
Conditions
Acute Myeloid Leukaemia
Trial Timeline
Apr 1, 2016 → Dec 1, 2032
NCT ID
NCT02724163About Gemtuzumab ozogamicin + Liposomal daunorubicin + Mitoxantrone + Fludarabine + Cytarabine + Busulfan + Cyclophosphamide
Gemtuzumab ozogamicin + Liposomal daunorubicin + Mitoxantrone + Fludarabine + Cytarabine + Busulfan + Cyclophosphamide is a phase 3 stage product being developed by Pfizer for Acute Myeloid Leukaemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT02724163. Target conditions include Acute Myeloid Leukaemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukaemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02724163 | Phase 3 | Recruiting |
Competing Products
20 competing products in Acute Myeloid Leukaemia